Hypermutation as a Factor Contributing to the Acquisition of Antimicrobial Resistance

Clinical Infectious Diseases

Volumn 37, Issue 9, 2003, Pages 1201-1209

  Blázquez, Jesús ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL MUTATION; BACTERIUM MUTANT; GENETIC RECOMBINATION; GENETIC SELECTION; GENETIC STABILITY; HYPERMUTATION; LABORATORY TEST; MATHEMATICAL MODEL; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SELECTION PRESSURE; STABLE HYPERMUTATION;

ANTI-BACTERIAL AGENTS; BACTERIA; CONJUGATION, GENETIC; DRUG RESISTANCE; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; RECOMBINATION, GENETIC;

EID: 0242407416     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/378810     Document Type: Review

References (74)

1. De la Cruz F, Davies J. Horizontal gene transfer and the origin of species: lessons from bacteria. Trends Microbiol 2000; 8:128-33.
2. Spratt BG. Resistance to antibiotics mediated by target alterations. Science 1994; 264:388-93.
3. Kohler T, Epp SF, Curty LK, et al. Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol 1999; 181:6300-5.
4. Poole K. Multidrug efflux pumps and antimicrobial resistance in P. aeruginosa and related organisms. J Mol Microbiol Biotechnol 2001; 3:225-64.
5. Cohen SP, McMurry LM, Hooper DC, et al. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob Agents Chemother 1989; 33:1318-25.
6. Livermore, D. M. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8:557-84.
7. Finken M, Kirschner P, Meier A, Wrede A, Bottger EC. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol 1993; 9:1239-46.
8. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647-50.
9. Van Rie A, Warren R, Mshanga I, et al. Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community. J Clin Microbiol 2001; 39: 636-41.
10. Rasmaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998; 79:3-29.
11. Blázquez J, Espinosa de los Monteros LE, Samper S, et al. Genetic characterization of multidrug-resistant Mycobacterium bovis strains from a hospital outbreak involving human immunodeficiency virus-positive patients. J Clin Microbiol 1997; 35:1390-3.
12. Guerrero A, Cobo J, Fortún J, et al. Nosocomial transmission of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection. Lancet 1997; 350:1738-42.
13. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288:1251-3.
14. Blázquez J, Morosini MI, Negri MC, González-Leiza M, Baquero F. Single amino acid replacements at positions altered in naturally occurring extended-spectrum TEM β-lactamases. Antimicrob Agents Chemother 1995; 39:145-9.
15. Blázquez J, Morosini MI, Negri MC, Baquero F. Selection of naturally occurring extended-spectrum TEM beta-lactamase variants by fluctuating beta-lactam pressure. Antimicrob Agents Chemother 2000; 44: 2182-4.
16. Medeiros, AA. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin Infect Dis 1997; 24: S19-S45.
17. Blázquez J, Baquero MR, Cantón R, Alós I, Baquero F. Characterization of a new TEM-type β-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli. Antimicrob Agents Chemother 1993; 37:2059-63.
18. Luria SE, Delbrück M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943; 28:491-511.
19. Newcombe H. Origin of bacterial variants. Nature 1949; 164:150-1.
20. Lederberg J, Lederberg EM. Replica plating and indirect selection of bacterial mutants. J Bacteriol 1952; 63:399-406.
21. Radman M., Taddei F, Matic I. Evolution-driving genes. Res Microbiol 2000; 151:91-5.
22. Kimura M. On the evolutionary adjustment of spontaneous mutation rates. Genet Res 1967; 9:23-34.
23. Leigh EG. The evolution of mutation rates. Genetics 1973; 73:1-18.
24. Drake JW. A constant rate of spontaneous mutation rates in DNA-based microbes. Proc Natl Acad Sci USA 1991; 88:7160-4.
25. Gibson TC, Scheppe ML, Cox EC. Fitness of an Escherichia coli mutator gene. Science 1970; 169:686-8.
26. Cox EC, Gibson TC. Selection for high mutation rates in chemostats. Genetics 1974; 77:169-84.
27. Chao L, Cox EC. Competition between high and low mutating strains of Escherichia coli. Evolution 1989; 37:125.
28. Taddei F, Radman M, Maynard-Smith J, et al. Role of mutator alleles in adaptive evolution. Nature 1997; 387:700-3.
29. Moxon, ER, Rainey PB, Nowak MA, Lenski RE. Adaptive evolution of highly mutable loci in pathogenic bacteria. Curr Biol 1994; 4: 24-33.
30. Leclerc JE, Li B, Payne WL, Cebula TA. High mutation frequencies among Escherichia coli and Salmonella pathogens. Science 1996; 274: 1208-11.
31. Matic I, Radman M, Taddei F, et al. Highly variable mutation rates in commensal and pathogenic E. coli. Science 1997; 277:1833-4.
32. Richardson AR, Stojiljkovic I. Mismatch repair and the regulation of phase variation in Neisseria meningitidis. Mol Microbiol 2001; 40: 645-55.
33. Prunier AL, Malbruny B, Laurans M, Brouard J, Duhamel JF, Leclercq R. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis 2003; 187:1709-16.
34. Oliver A, Baquero F, Blázquez J. The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol 2002; 43: 1641-50.
35. Brégeon D, Matic I, Radman M, Taddei F. J Genet 1999; 78:21-28.
36. Horst JP, Wu T, Marinus MG. Escherichia coli mutator genes. Trends Microbiol 1999; 7:29-36.
37. Modrich P, Lahue R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem 1996; 65: 101-33.
38. Matic I, Rayssiguier C, Radman M. Interspecies gene exchange in bacteria: the role of SOS and mismatch repair systems in evolution of species. Cell 1995; 80:507-15.
39. Rayssiguier C, Thaler DS, Radman M. The barrier to recombination between Escherichia coli and Salmonella typhimurium is disrupted in mismatch-repair mutants. Nature 1989; 342:396-401.
40. Townsend JP, Nielsen KM, Fisher DS, Hartl DL. Horizontal acquisition of divergent chromosomal DNA in bacteria: effects of mutator phenotypes. Genetics 2003; 164:13-21.
41. Claverys JP, Prudhomme M, Mortier-Barriere I, Martin B. Adaptation to the environment: Streptococcus pneumoniae, a paradigm for recombination- mediated genetic plasticity? Mol Microbiol 2000; 35: 251-9.
42. Dowson CG, Coffey TJ, Spratt BG. Origin and molecular epidemiology of penicillin-binding-mediated resistance to β-lactam antibiotics. Trends Microbiol 1994; 2:361-6.
43. Claverys JP, Lacks SA. Heteroduplex deoxyribonucleic acid base mismatch repair in bacteria. Microbiol Rev 1986; 50:133-65.
44. Humbert O, Parudhomme M, Hakenbeck R, Dowson CG, Claverys JP. Homeologous recombination and mismatch repair during transformation in Streptococcus pneumoniae: saturation of the Hex mismatch repair system. Proc Natl Acad Sci USA 1995; 92:9052-6.
45. Grebe T, Hakenbeck R. Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resisance determinants for different classes of beta-lactam antibiotics. Antimicrob Agents Chemother 1996; 40:829-34.
46. Coffey TJ, Daniels M, McDougal LK, Dowson CG, Tenover FC, Spratt BF. Genetic analysis of clinical isolates of Streptococcus pneumoniae with high level resistance to expanded-spectrum cephalosporins. Antimicrob Agents Chemother 1995; 39:1306-13.
47. Kraub J, Hakenbeck R. A mutation in the D,D-carboxypeptidase penicillin-binding protein 3 of Streptococcus pneumoniae contributes to cefotaxime resistance of the laboratory mutant C604. Antimicrob Agents Chemother 1997; 41:936-42.
48. Courcelle J, Khodursky A, Peter B, Brown PO, Hanawalt PC. Comparative gene expression profiles following UV exposure in wild-type and SOS-deficient Escherichia coli. Genetics 2001; 158:41-64.
49. Friedberg EC, Wagner R, Radman M. Specialized DNA polymerases, cellular survival, and the genesis of mutations. Science 2002; 296: 1627-30.
50. Sutton MD, Smith BT, Godoy VG, Walker GC. The SOS response: recent insights into umwDC-dependent mutagenesis and DNA damage tolerance. Annu Rev Genet 2000; 34:479-97.
51. Boshoff, HIM, Reed MB, Barry CE III, Mizrahi V. DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell 2003; 113:183-93.
52. Vulic M, Dionisio F, Taddei F, Radman M. Molecular keys to speciation: DNA polymorphism and the control of genetic exchange in enterobacteria. Proc Natl Acad Sci USA 1997; 94:9763-7.
53. Matic I, Taddei F, Radman M. No genetic barriers between Salmonella enterica serovar Typhimurium and Escherichia coli in SOS-induced mismatch repair-deficent cells. J Bacteriol 2000; 182:5922-4.
54. Li B, Tsui HCT, LeClerc JE, et al. Molecular analysis of mutS expression and mutation in natural isolates of pathogenic Escherichia coli. Microbiology 2003; 149:1323-31.
55. Bjedov I, Tenaillon O, Gerard B, et al. Stress-induced mutagenesis in bacteria. Science 2003; 300:1404-9.
56. Karunakaran P, Davies J. Genetic antagonism and hypermutability in Mycobacterium smegmatis. J Bacteriol 2000; 182:3331-5.
57. Björkman J, Nagaev I, Berg OG, Hughes D, Andersson DI. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 2000; 287:1479-82.
58. Böttger EC, Springer B, Pletschette M, Sander P. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat Med 1998; 4:1343-4.
59. Mao EF, Lane L, Lee J, Miller JH. Proliferation of mutators in a cell population. J Bacteriol 1997; 179:417-22.
60. Giraud A, Matic I, Radman M, Fons M, Taddei F. Mutator bacteria as a risk factor in treatment of infectious diseases. Antimicrob Agents Chemother 2002; 46:863-5.
61. Gilligan PH. Microbiology of cystic fibrosis lung disease. In: Yankaskas and Knowles, eds. Cystic fibrosis in adults. Philadelphia: Lippincott-Raven, 1999:93-114.
62. Rosche WA, Foster P. Mutation under stress: adaptive mutation in Escherichia coli. In: Bacterial stress responses. Storz G and Hengge-Aronis R, eds. Washington DC: ASM Press, 2000.
63. Phillips I, Culebras E, Moreno F, Baquero F. Induction of the SOS response by new 4-quinolones. J Antimicrob Chemother 1987; 20: 631-8.
64. Piddock LJ, Wise R. Induction of the SOS response in Escherichia coli by 4-quinolone antimicrobial agents. FEMS Microbiol Lett 1987; 41: 289-94.
65. Ysern P, Clerch B, Castaño M, Gilbert I, Barbé J, Llagostera M. Induction of SOS genes in Escherichia coli and mutagenesis in Salmonella typhimurium by fluoroquinolones. Mutagenesis 1990; 5:63-6.
66. Ren L, Rahman MS, Humayun MZ. Escherichia coli cells exposed to streptomycin display a mutator phenotype. J Bacteriol 1999; 181: 1043-4.
67. Baquero MR, Gómez-Gómez JM, Lobo M, Baquero F, Blázquez J. β-lactams induce dinB (error-prone DNA-polymerase IV) transcription in Escherichia coli, resulting in a mutator phenotype [abstract 1804]. In: Programs and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington DC: American Society for Microbiolgoy, 2001:99.
68. Schaaff F, Reipert A, Bierbaum G. An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46:3540-8.
69. O'Neill AJ, Chopra I. Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low. J Antimicrob Chemother 2002; 50:161-9.
70. O'Neill AJ, Chopra I. Lack of evidence for involvement of hypermutability in emergence of vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:1484-5.
71. Bierbaum G, Reipert A, and Schaaff F. Authors reply. Antimicrob Agents Chemother 2003; 47:1485.
72. Tanabe K., Kondo T, Onodera Y, Furusawa M. A conspicuous adaptability to antibiotics in the Escherichia coli mutator strain, dnaQ49. FEMS Microbiol Lett 1999; 176:191-6.
73. Garau J, Xercavins M, Rodriguez-Carballeira M, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999; 43:2736-41.
74. Wang H, Dzink-Fox JL, Chen M, Levy SB. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother 2001; 45:1515-21.